Oncogene 2008,27(48):6252–6275 PubMedCrossRef 30 Ghobrial IM, Wi

Oncogene 2008,27(48):6252–6275.PubMedCrossRef 30. Ghobrial IM, Witzig TE, Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005, 55:178–194.PubMedCrossRef 31. Szegezdi E, Fitzgerald U, Samali : Caspase-12 and ER stress mediated apoptosis: the story so far. Ann NY Acad Sci 2003, 1010:186–194.PubMedCrossRef JQ-EZ-05 32. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57–70.PubMedCrossRef 33. Gross A, McDonnell JM, Korsmeyer SJ: BCL-2 family members and the

mitochondria in apoptosis. Genes Dev 1999, 13:1899–1911.PubMedCrossRef 34. Minn AJ, Vélez P, Schendel SL, Liang H, Muchmore SW, Fesik SW, Fill M, Thompson CB: Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature 1997,385(6614):353–357.PubMedCrossRef 35. Dewson Selleck Luminespib G, Kluc RM: Bcl-2 family-regulated apoptosis in health and disease. Cell Health and Cytoskeleton

2010, 2:9–22. 36. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo . Cancer Res 1995, 55:4438.PubMed 37. Fulda S, Meyer E, Debatin KM: Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2000, 21:2283–2294.CrossRef 38. Minn AJ, Rudin CM, Boise LH, Thompson CB: Expression of Bcl-XL can confer a multidrug resistance phenotype. Blood 1995, 86:1903–1910.PubMed 39. Miquel C, Borrini F, Grandjouan S, Aupérin A, Viguier J, Velasco V, Duvillard P, Praz F, Sabourin JC: Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. Am J Clin Pathol 2005,23(4):562–570.CrossRef

40. Goolsby C, Paniagua M, Tallman M, Gartenhaus RB: Bcl-2 regulatory pathway is functional in chronic lymphocytic leukaemia. Cytometry B Clin Cytom 2005,63(1):36–46.PubMed 41. Pepper C, Hoy T, Bentley DP: Bcl-2/Bax ratios in chronic lymphocytic see more leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997,76(7):935–938.PubMedCrossRef 42. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 1991,351(6326):453–456.PubMedCrossRef 43. Bai L, Zhu WG: p53: structure, function and therapeutic find more applications. J Cancer Mol 2006,2(4):141–153. 44. Oren M, Rotter V: Introduction: p53–the first twenty years. Cell Mol Life Sci 1999, 55:9–11.PubMedCrossRef 45. Lane DP: p53, guardian of the genome. Nature 1992, 358:15–16.PubMedCrossRef 46. Avery-Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, Talseth-Palmer BA, Rizos H, Zhang XD, Scott RJ, Hersey P: p53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer 2011, 11:203.PubMedCrossRef 47.

Comments are closed.